Multiple sclerosis (MS) is an autoimmune demyelinating disease of the human central nervous system (CNS), mainly affecting young adults. Among the immunomodulatory disease modifying treatments approved up to date to treat MS, IFN-β remains to be one of the most widely prescribed for the Relapsing-Remitting (RR) variant of the disease, although its mechanism of action is still partially understood. RR-MS variant is characterized by phases with increasing neurological symptoms (relapses) followed by periods of total or partial recovery (remissions), which implies the existence of immunomodulatory agents to promote the relapsing-to-remitting transition. Among these agents, it has been described the immunosuppressive role of a heterogeneous population of immature myeloid cells, namely the myeloid-derived suppressor cells (MDSCs) during the clinical course of the experimental autoimmune encephalomyelitis (EAE), the most used MS model to study RRMS. However, it is still unknown how the current MS disease modifying treatments, e.g. IFN-β, affects to MDSCs number or activity. Our present results show that a single injection of IFN-β at the onset of the clinical course reduces the severity of the EAE, enhancing the presence of MDSCs within the smaller demyelinated areas. Moreover, the single dose of IFN-β promotes MDSC immunosuppressive activity both in vivo and in vitro, augmenting T cell apoptosis. Finally, we show that IFN-ß preserves MDSC immaturity, preventing their differentiation to mature and less suppressive myeloid cell subsets. Taking together, all these data add new insights into the mechanism of IFN-β treatment in EAE and point to MDSCs as a putative endogenous mediator of its beneficial role in this animal model of MS.
Introduction
The most frequent primary demyelinating disease is multiple sclerosis (MS), an autoimmune, inflammatory and chronic disease of the central nervous system (CNS) that affects about 2,500,000 people worldwide (Sospedra and Martin, 2005) . The clinical onset of MS typically occurs between 20 and 40 years of age and it is characterized by demyelination, axonal damage, oligodendrocyte death and neurological affectations. Relapsing-remitting MS (RRMS) is the most frequent form of the disease, in which an exacerbation of the symptoms (relapses) is followed by phases of remission. This would suggest the existence of molecules or specific cell types that control the immune system's activity (Meyer et al., 2017; Weissert, 2017) , and eventually, (re)myelination. Murine experimental autoimmune encephalomyelitis (EAE) is the most common animal model for MS and it is based on a MHC class II-restricted CD4 + /CD8 + T-cell mediated self-reaction against compo-inflammatory reaction within the CNS leads to focal demyelination and oligodendrocyte death, followed by axonal damage. Interestingly, the existence of remitting phases in the EAE models implies the existence of immune-modulation that has been associated with the activity of different cell types: regulatory T cells (Treg; both CD4 + and CD8 + ), M2 macrophages, γδT cells and activated invariant NKT cells (Koutrolos et al., 2014; Ortega et al., 2013; Parekh et al., 2013) . However, the role of a novel population of regulatory myeloid cells, namely myeloid-derived suppressor cells (MDSCs), and their activity in the context of EAE is still only partially understood (Melero-Jerez et al., 2016; Moliné-Velázquez et al., 2011; Moliné-Velázquez et al., 2014; MolineVelazquez et al., 2016) .
A standardized nomenclature has been established to describe the two main populations of MDSCs based on their morphological and phenotypical features (Bronte et al., 2016) Ly-6G -/low phenotype. Due to the difficulty in the discrimination of PMN-MDSCs from mature neutrophils (Bronte et al., 2016) , the research on MDSCs in EAE has been mainly centralized on M-MDSCs (Moliné-Velázquez et al., 2011; Moliné-Velázquez et al., 2014; Zhu et al., 2007; Zhu et al., 2011) , which indeed show a higher immunosuppressive activity when assessed in a per cell analysis (Dolcetti et al., 2010; Movahedi et al., 2008; Youn et al., 2008) . In EAE, MMDSCs have been described to be CD11b + Ly-6C
high Ly-6G −/low in both the spleen and CNS of the mice at the peak of their clinical course (Moliné-Velázquez et al., 2011; Zhu et al., 2007 Zhu et al., , 2011 . MDSCs share their phenotype with inflammatory immature monocytes, which are highly plastic during the immune processes that drive EAE. In fact, half of the CD11b + Ly-6C high Ly-6G −/low cells associated with the onset of the clinical course behave as MDSCs by suppressing the inflammatory process at the peak of the disease (Giles et al., 2018; Zhu et al., 2011) . MDSCs exert their effects on T cells by either inhibiting their proliferation or by inducing their anergy/apoptosis through cell-cell interactions, and with maximal activity at the peak of clinical disability (Moliné-Velázquez et al., 2011) . T cell proliferation is suppressed by the production of Arginase-I (Arg-I: Moliné-Velázquez et al., 2011) and nitric oxide (NO) by MDSCs in an Interferon-γ (IFN-γ) mediated manner (Zhu et al., 2007 (Zhu et al., , 2011 , and can be antigen-specific (Casacuberta-Serra et al., 2016) . In healthy conditions, MDSCs present in the bone marrow normally polarize towards the different mature myeloid cell subsets. However, in cancer, but also in the context of EAE, MDSC differentiation is arrested, which is crucial to exert their potent immunosuppressive role in this animal model of MS (Gabrilovich et al., 2012; Moliné-Velázquez et al., 2011) . The use of induced MDSCs in future therapeutic strategies is an active field of research in MS (Casacuberta-Serra et al., 2017; Gomez et al., 2014) . However, in the case of endogenous MDSCs from MS patients (Iacobaeus et al., 2018) it will be important to check the unexplored effects of established molecular therapies for MS on this very plastic immune cell type. Type I IFN-β is still used as the first line treatment for MS (Prinz et al., 2008) and it successfully reduces the frequency of clinical exacerbations by about 35% in patients at the onset of their neurological symptoms who are likely to convert into clinically defined-MS. Indeed, IFN-β decreases the lesion load as measured by MRI and it delays the progression of neurological disability (Arnason, 2005; Comi et al., 2001) . The role of IFN-ß as a disease ameliorating agent in EAE has been explored extensively (Galligan et al., 2010; Martin-Saavedra et al., 2007; Suardíaz et al., 2016) . As such, IFN-ß reduces the proliferation of autoreactive CD4 + T cells against myelin epitopes (Gallina et al., 2006) , it affects inflammatory cell infiltration by preserving the bloodbrain barrier (BBB: Cheng et al., 2015; Stone et al., 1995) , it interferes with the production of matrix metalloproteinases (Mastronardi et al., 2004; Waubant et al., 2003) , it reduces the CD4 + T-cell production of proinflammatory cytokines like IFN-γ (Mastronardi et al., 2004; Waubant et al., 2003) , it inhibits Th17 polarization, it induces Th2 cell immune shifting (Kozovska et al., 1999) , and it modifies the cytokine and chemokine expression profile during EAE (Cheng et al., 2015; Galligan et al., 2010; Martin-Saavedra et al., 2007; Sweeney et al., 2011 ; for a review see Kasper and Reder, 2014) . Myeloid cells represent potential targets for endogenously produced IFN-ß. The multiple effects of type I interferons on different myeloid subsets are well established (Brendecke and Prinz, 2012) , both during the hematopoietic processes (Sonda et al., 2011) and in pathological conditions. Indeed, selective defects in one of its receptor subunits (IFNAR1) on myeloid cells leads to a severe disease, with a deteriorated effector phase and enhanced lethality (Prinz et al., 2008) . Importantly, monocytes and macrophages, and their equivalent within the CNS, microglia, are IFNAR-dependent cells with pivotal roles in CNS immunity. Furthermore, IFNAR signaling participates in the myelin phagocytosis at the cellular level (Prinz et al., 2008) . However, there is no data about the effect of IFN-β in MDSCs.
In the current study, we present novel data in the context of EAE indicating that the immunosuppressive activity of MDSCs is promoted after IFN-ß treatment, adding new insights into the modulation of MDSCs and providing a new perspective that could have important therapeutic consequences for the development of future cell-based therapies for MS.
Materials and methods

Induction of EAE
For in vivo IFN-ß treatment, female six-week-old C57/BL6 mice were purchased from Harlan Laboratories (Harlan, Udine, Italy). Chronic Progressive EAE was induced by subcutaneous immunization with 200 μg of Myelin Oligodendrocyte Glycoprotein (MOG 35-55 peptide: GenScript. New Jersey, USA) emulsified in complete Freund's adjuvant (CFA) containing 4 mg of heat inactivated Mycobacterium tuberculosis (BD Biosciences, Franklin Lakes, New Jersey, USA) and at a final volume of 200 μl. Immunized mice were administered Pertussis toxin (250 ng/mouse, Sigma-Aldrich, St. Louis, MO, USA), injected intravenously through the tail vein on the day of immunization and 48 h later. EAE was scored clinically on a daily basis in a double-blind manner as follows: 0, no detectable signs of EAE; 1, paralyzed tail; 2, weakness or unilateral partial hindlimb paralysis; 3 complete bilateral hindlimb paralysis; 4, total paralysis of forelimbs and hindlimbs; and 5, death.
At the onset of the symptoms (described as a clinical score between 0.5 and 1.5), EAE-induced animals received a single intraperitoneal injection of 10,000 units (40 ng) recombinant murine IFN-ß (Mouse Interferon Beta, mammalian, carrier-free: PBL Interferon source, Piscataway, NJ, USA) resuspended in 200 μl of saline, and they were sacrificed three days later with a lethal dose of pentobarbital.
All animal manipulations were approved by the institutional ethical committees (Comité No. 1946 No. / 2003 , and with the Spanish National and Regional Guidelines for Animal Experimentation and the Use of Genetically Modified Organisms (RD 53/2013 and 178/2004 , Ley 32/2007 and 9/2003 , Decreto 320/2010 .
Immunohistochemisty
After sacrifice, fresh segments of the thoracic spinal cord were placed in 4% paraformaldehyde (PFA: Sigma-Aldrich) for 48 h at room temperature (RT). After immersion in 30% (w/v) sucrose diluted in 0.1 M Phosphate Buffer, pH 7.4 (PB) for 12 h, coronal cryostat sections (20 μm thick: Leica, Nussloch, Germany) were thaw-mounted on Superfrost®Plus slides. After several rinses with PB, the sections were pre-treated for 15 min with 10% methanol in PB and they were preincubated for 1 h at RT in incubation buffer: 5% appropriate normal serum (Vector, Burlingame, USA) and 0.2% Triton X-100 (Merck) diluted in phosphate buffered saline (PBS). Immunohistochemistry was performed by incubating the sections overnight at 4°C with the primary antibodies diluted in incubation buffer (Table 1) . After rinsing, the sections were then incubated with the corresponding fluorescent (1:1000, Invitrogen, Paisley, UK) or biotinylated (1:200, Vector) secondary antibodies in incubation buffer for 1 h at RT. For Gr-1 staining, antibody binding was detected with biotinylated secondary antibody followed by the Vectastain Elite ABC reagent (Vector) and a FITC-labeled Streptavidin (Jackson ImmunoResearch, Suffolk, UK). In the case of Gr-1, additional blockade of endogenous avidin and biotin was performed prior to primary antibody incubation. For PD-L1 staining, primary antibodies were incubated during 96 h. Apoptosis was assayed by TUNEL, using the ApoTag® Plus Fluorescein in situ Apoptosis Detection Kit (Millipore, Billerica, MA, USA) according to manufacturer's instructions. In all cases, cell nuclei were stained with Hoeschst 33,342 (10 μg/ml, Sigma-Aldrich) and the sections were mounted with coverslips in Fluoromount-G (Southern Biotech, Birmingham, AL, USA).
Cell count and fluorescence intensity measurement
The total number of cells within the CNS tissue was assessed using a Leica confocal microscopy application (Suite 2.7.0 R1), manually couting cells in 3 sections (separated by 340 μm) of spinal cord from each animal. Pictures were acquired with a confocal SP5 microscope located at the Microscopy Service of the Hospital Nacional de Parapléjicos, with a z distance between planes of 1 μm, and cells were counted avoiding their overlap. All the lesions in the section were included in the analysis, and the total number of cells was considered in terms of the infiltrated area (measured with ImageJ software). Cellular positive labeling was considered only when it clearly surrounds a cell nucleus. For Gr-1, CD124, MHC-II and PD-L1 staining, we analyzed the intensity of fluorescence, measuring the average pixel intensity of 15-20 cells per lesion with ImageJ measurement tool.
Flow cytometry analysis of splenic populations
Fresh spleens from MOG-immunized mice were obtained at the peak of their clinical symptoms or three days after IFN-ß administration. The tissue was homogenized to single cell suspension, passed through a 40 μm nylon cell strainer (BD Biosciences) and washed in RPMI medium (Gibco-Thermo Fisher Scientific, Waltham, MA USA) supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS: Gibco) and 1% penicillin/streptomycin (P/S: Gibco). After erythrocyte lysis in ACK lysis buffer (8.29 g/l NH 4 Cl, 1 g/l KHCO 3 , 1 mM EDTA in distilled H 2 O at pH 7.4: Panreac, Barcelona, Spain), 2 × 10 6 splenocytes were resuspended in 50 μl of staining buffer (sterile 1× PBS supplemented with 10% FBS, 25 mM HEPES buffer and 2% P/S: Gibco) and the Fc receptors were blocked for 10 min at 4°C with anti-CD16/CD32 antibodies (10 μg/ml: BD Biosciences). After blocking, the cells were labeled for 30 min at 4°C in the dark with 50 μl of the corresponding antibody panel in staining buffer (Table 1) : a Pacific Blue conjugated hamster anti-mouse CD3, a FITC conjugated rat anti-mouse Ly-6C, a R-PE conjugated rat anti-mouse Ly-6G, a PErCP-Cy5.5 conjugated rat antimouse CD11b (all from BD Biosciences), an APC conjugated hamster anti-mouse CD69, an APC conjugated mouse anti-mouse CD11c, and an e-Fluor-450 conjugated mouse anti-mouse F4/80 (from eBioscienceThermo Fisher Scientific). The splenocytes were then washed twice with staining buffer, recovered by centrifugation at 1500 rpm for 5 min at RT, resuspended in PBS and finally passed through a FACS Canto II cytometer (BD Biosciences) located at the Flow Cytometry Service of the Hospital Nacional de Parapléjicos. Both the percentages and the mean fluorescence intensity (MFI) of the cells were analyzed using FlowJo 7.6.4 software (Tree Star Inc. Ashaland, OR, USA).
Isolation of splenic Ly-6C high -cells/MDSCs and T lymphocytes
Splenocytes were obtained from control (for T lymphocytes) or MOG-immunized C57BL/6 mice either at the onset (clinical score 0.5-1.5) or at the peak of clinical score (≥3 for MDSCs), as described previously (Moliné-Velázquez et al., 2011; Moliné-Velázquez et al., 2014) . For T cell isolation, the splenocytes were resuspended in sorting buffer (sterile 1× PBS with 10% FBS, 25 mM HEPES and 2% P/S: 
FN-β treatment of Ly-6C high -cells/MDSCs alone or in co-culture with T lymphocytes or splenocytes
For T cell activation, flat bottom 96-well plates were coated with purified anti-CD3e/CD28 antibodies (1 μg/ml each; BD Biosciences) for 3 h at 37°C. Purified CD3 + T cells (2 × 10 5 /well) were plated in RPMI medium (Gibco) supplemented with 10% FBS, 25 mM HEPES, 1% Lglutamine, 1% P/S (Gibco) and 50 μM 2-ME (Sigma), and stimulated for 14 h with anti-CD3e/CD28 (or culture medium alone for the unstimulated controls). Isolated MDSCs were resuspended in IMDM medium (BioWest, Nuaillé, France) supplemented with 2 mM L-glutamine, 1% P/S, 10% FBS (Gibco) and 50 μM 2-ME (Sigma), plated in flat bottom 96-well plates at a density of 5 × 10 4 (1:4, MDSCs:T cells) or 2 × 10 4 (1:10), and stimulated with IFN-β (1,000 U/ml) or saline serum for 6 or 18 h. Subsequently, the culture medium was removed and T cells (or fresh medium in the case of culture of MDSCs alone) were added for a further 48 h. The cells were harvested at different time points (0, 6, 18 and 72 h) by centrifugation at 2000 rpm at RT, washed in 1× PBS and analyzed for either myeloid (CD11b, CD11c, MHC-II, F4/80, Ly-6C and Ly-6G: Table 1 ) markers or process for cell viability analysis. In this case, cells were fixed in 70% ethanol at −20°C, and stained the following day with a propidium iodide/RNase solution (Immunostep, Salamanca, Spain) according to the manufacturer's instructions. The cells were then analyzed in a FACS Canto II cytometer with FACS Diva 6.1 software, recording 30,000 events. For MOG-induced stimulation, splenocytes were obtained from MOG-immunized C57BL/6 mice at the peak of clinical score (≥3), as described previously (Moliné-Velázquez et al., 2011; Moliné-Velázquez et al., 2014) and were plated in IMDM (BioWest, Nuaillé, France) supplemented with 2 mM L-glutamine, 1% P/S, 10% FBS (Gibco) and 50 μM 2-ME (Sigma), plated in U-bottom 96-well plates at a density of 2 × 10 5 . Splenocytes were exposed to 5 μM Tag-it Violet™ Proliferation and Cell Tracking Dye (Biolegend) diluted in PBS supplemented with 0.1% BSA at 37°C for 20 min protected from light. After washing, splenocytes were stimulated for 18 h with 5 μg/mL MOG (or culture medium alone for the unstimulated controls). Isolated Ly-6C high -cells/ MDSCs were resuspended in IMDM medium (BioWest, Nuaillé, France) supplemented with 2 mM L-glutamine, 1% P/S, 10% FBS (Gibco) and 50 μM 2-ME (Sigma), plated in U-bottom 96-well plates at a density of 5 × 10 4 (1:4, MDSCs:splenocytes) and stimulated with IFN-β (1,000 U/ ml) or saline serum for 18 h (in presence/absence of 5 μg/ml MOG in the case of Ly-6C high -cells). Subsequently, the culture medium was removed and splenocytes (or fresh medium in the case of culture of Ly-6C high -cells/MDSCs alone) were added for further 48 h. After that, cells were harvested by centrifugation at 1500 rpm at RT, washed in 1× PBS stained with PErCP-Cy5.5-conjugated rat anti-mouse CD11b and APC conjugated hamster anti-mouse CD3 (BD Bioscience) and fixed with 0.1% PFA. At least, 30,000 events were acquired in FACS Canto II flow cytometer (Becton Dickinson, USA) and analyzed with the FacsDiva software (Becton Dickinson, USA).
In vitro analysis of the immunosuppressive activity of MDSCs from IFN-ß treated mice
To analyze the immunosuppressive activity of MDSCs from IFN-ß treated animals, a different set of EAE mice with a clinical score ranging from 0.5 to 1.5 were injected intraperitoneally with 10,000 units of recombinant murine IFN-β (EAE-IFN-β) or saline (EAE-Veh). The mice were sacrificed three days later and their spleen was dissected out for MDSC extraction by FACS. Sorted MDSCs were immediately plated over control/activated CD3 + T cells (see above), cultured at a density of 2 × 10 5 cells per well for 24 h at a ratio of 1:4 (MDSCs:T cells) and 48 h later, they were collected and analyzed for myeloid (CD11b, CD11c, MHC-II, F4/80, Ly-6C and Ly-6G) or cell viability staining, as described previously.
Statistical analysis
The data are expressed as the mean ± SEM and they were analyzed with SigmaPlot version 11.0 (Systat Software, San Jose, CA, USA). Student's t-test was used to compare pairs of the different groups of mice and cell cultures, or using a Mann-Whitney U test for non-parametric data, and one way ANOVA test was used for multiple comparisons. Pearson's product was obtained for the correlation analyses. Minimal statistical significance was set at p < .05: * or # p < .05; ** p < .01; *** or ### p < .001.
Results
The peripheral and CNS MDSCs augments after a single injection of IFN-ß
It is known that the treatment with IFN-ß eases the clinical course of EAE mice (Cheng et al., 2015) . Here, a single injection of IFN-β when these animals showed a clinical score between 0.5 and 1.5 significantly reduced the clinical score of the animals from the first day post injection until the peak maximal disability of the EAE-Veh animals (Fig. 1A) . To explore whether this effect may be related to MDSCs, we examined the peripheral immune system, i.e. principally the spleen (Fig. 1B-E) . There was no difference in the global number of splenocytes between treated or vehicle-administered (control) mice (Fig. 1B) , or in the total number of myeloid cells per spleen ( Fig. 1C-E) . By contrast, the percentage of MDSCs within the myeloid subset (Ly6C high Ly6G −/low cells, gated on CD11b) of EAE-IFN-β mice was significantly higher (9.6 ± 1.0, n = 7) than in the control mice (6.7 ± 0.5, n = 4, p < .05: Fig. 1D-E Fig. 2A) , the proportion of CD3 + T cells was significantly lower after the treatment (vehicle: 27.5 ± 3.1, n = 4; IFN-β: 19.9 ± 1.5, n = 7, p < .05: Fig. 2B-C ), without affecting their activity state ( Fig. 2D-E ). These data reinforced the idea of MDSCs as endogenous modulators of the lymphocyte populations, consistent with the strong inverse correlation between the MDSC and T cell component (Fig. 2F) . Moreover, IFNAR1, the most common receptor for Type I IFNs (α/β: (Pogue et al., 2004; Schreiber, 2017) , was present in half of the splenic CD11b + Ly-6C high Ly-6G −/low cells from EAE mice with a clinical score between 0.5 and 1.5 (when in vivo treatments were administered), the same proportion as T cells but more than the global myeloid subset or neutrophils ( Fig. 3A-B ). Comparing both CD11b ). An initial analysis indicated that the injured area in the EAE-IFN-β animals (7581 ± 1797 μm 2 ) was significantly smaller than in the EAE-Veh controls (13,561 ± 2,042 μm 2 ; p < .05), and the infiltrated area was mostly confined to the ventral tracts and not infiltration was evident dorsolaterally (Fig. 4A-B) . As shown previously, Arg-I can be considered as a marker of MDSCs in the spinal cord of EAE mice at the peak of the disease (Moliné-Velázquez et al., 2011; Moliné-Velázquez et al., 2014) . Interestingly, while both control and EAE-IFN-β mice had Arg-I + cells in their lesions, they were more evident after IFN-β treatment ( Fig. 4A-E) . In fact, the significant inverse correlation observed in control mice between the infiltrated area and the density of Arg-I + cells was even stronger after IFN-β treatment (EAE-Veh: r = −0.314; p < .01; EAE-IFN-β: r = −0.642; p < .00001; Fig. 4F ). Together, these data point to MDSC enrichment in both the peripheral immune system and the target tissue (i.e.: the CNS) after a single-dose of IFN-ß.
MDSCs are enriched in the spinal cord myeloid infiltrate of IFN-β treated EAE mice
In order to check whether the phenotype and/or the function of MDSCs were modified after IFN-β treatment, we analyzed the different phenotypes and the activity-associated markers present in these cells: CD11b, Gr-1 and CD124 (IL-4Rα). CD11b is the most common marker of differentiation at the surface of myeloid cells, including MDSCs (Zhu et al., 2007 Fig. 5A-L) . However, the composition of the whole myeloid component in the EAE-IFN-β mice was strikingly different from the EAE-Veh control mice. Whereas in EAE-Veh animals the density of (Fig. 5N ).
To further analyze the phenotype of the CD11b + Arg-I + subset, we assessed the surface expression of two useful markers of MDSC activity, namely Gr-1 and CD124 (Gallina et al., 2006) . As for CD11b, all Arg-I + cells within the infiltrated area had faint Gr-1 immunoreactivity ( Fig. 6A-F Fig. 6G ). CD124 is also an indicator of the higher capacity of MDSC immunosuppression in cancer (Gallina et al., 2006; Kohanbash et al., 2013; Yang et al., 2006) and EAE (Moliné-Velázquez et al., 2014) . Although all Arg-I + cells were immunostained for CD124 (Fig. 6H-M) , it was more intense in the cells from EAE-IFN-β cells (61.3 ± 2.0), than in the cells from the EAE-Veh mice (43.1 ± 1.8; p < .001: Fig. 6N ). In order to check whether this change in the immunosuppressive phenotype can have a parallel on MDSC activity over T cells, double labeling of MHC-II and PD-L1 were carried out in Arg-I + cells. MDSCs have been ascribed a poor antigen presenting capacity (Gabrilovich et al., 2012; Zhu et al., 2011) . Interestingly, we detected a significant decrease in the percentage and MFI ratio of MHC-II immunolabelling of Arg-I + cells Together these data strongly suggest that the immunosuppressive phenotype of MDSCs is promoted after a single dose of IFN-ß within the CNS of EAE mice.
MDSCs present a promoted T cell suppressive activity after IFN-ß treatment
In order to check whether the modulation of MDSCs towards a stronger suppressive phenotype occurred in vivo after IFN-ß administration, we performed an in vitro assay with MDSCs obtained from EAEVeh or EAE-IFN-β mice. EAE mice with a clinical score ranging 0.5 to 1.5 received a single injection of IFN-β (10,000 units) or the vehicle alone, and their spleen was removed three days later. MDSCs isolated from the EAE mice that received saline (MDSC-Veh) or IFN-β (MDSC-IFN-β) were co-cultured for 48 h with control or anti-CD3e/CD28 preactivated T cells in a 1:4 ratio (MDSC:lymphocytes: Fig. 9A-B) . Propidium iodide analysis of cell viability test indicated that MDSC-IFN-β significantly increased the dead (EAE-Veh: 0.5 ± 0.1; EAE-IFN-β: 0.76 ± 0.17, p < .05: Fig. 9B′ ) or apoptotic T cells (EAE-Veh: 17.3 ± 2.5; EAE-IFN-β: 25.0 ± 3.0, p < .05: Fig. 9B″ ), in conjunction with a significant reduction in the proportion of viable T cells (EAEVeh: 82.2 ± 2.5; EAE-IFN-β: 74.2 ± 3.2, p < .05: Fig. 9B″′ ).
Interestingly, there were no changes in the dead, apoptotic or viable control T cells when they were exposed to MDSC-Veh or MDSC-IFN-β (Fig. 9B ). In conclusion, MDSCs from mice that were administered IFN-β were not only more abundant but they also had a stronger in vitro immunosuppressive effect over activated T cells.
In order to check whether the potentiation of the immunosuppressive role of MDSCs at the peak might be related to a specific role of IFN-β at the therapeutic window for its administration, splenic Ly-6C high -cells isolated at the onset of the EAE course (clinical score 0.5-1.5) were pre-treated with saline (Ly-6C high -Veh) or IFN-β (Ly-6C high -IFN-β) during 18 h either in the presence or absence of 5 μg/ ml MOG. Subsequently, the Ly-6C high -cells were co-cultured with 5 μg/ mL MOG pre-activated splenocytes from EAE mice at the peak of the clinical course in a proportion of 1:4 (MDSCs:splenocytes), and cell proliferation was assessed (Fig. 9C) . The Ly-6C high -Veh provoked significantly stronger proliferation in MOG-activated T cells than in the splenocytes alone, which was abrogated in presence of Ly-6C high -IFN-ß (Proliferation index: Stimulated splenocytes alone: 6.1 ± 0.6; Ly-6C high -Veh 10.5 ± 2.5; Ly-6C high -IFN-ß: 7.9 ± 1.0; Fig. 9D ). Remarkably, this effect was independent of the pre-exposition of Ly-6C high -cells to MOG (Ly-6C high -Veh + MOG: 8.8 ± 0.8; Ly-6C high -IFN-ß + MOG: 7.3 ± 0.8). These data indicate that the pro-inflammatory effect of Ly-6C high -cells at the onset of the disease can be blocked, or at least, reduced, in presence of IFN-ß.
In order to determine if this enhanced immunosuppression could also be induced in vitro, we designed an assay in which MDSCs extracted from EAE mice at the peak of their disability were pre-treated with saline (MDSC-Veh) or IFN-ß (MDSC-IFN-ß) for 18 h prior to co-culture. Subsequently, the MDSCs were co-cultured with either control, antiCD3e/CD28 activated CD3 + T cells from control mice or MOG-preactivated splenocytes from EAE mice at the peak of the disease in a proportion of 1 MDSC:4 T cells/splenocytes), and cell viability or a proliferation assay was assessed (Fig. 10A, D) . The MDSCs-IFN-ß provoked significantly stronger cell death (MDSCs-Veh: 0.5 ± 0.1; MDSC-IFN-β: 1.6 ± 0.3, p < .01) or apoptosis (MDSC-Veh: 33.6 ± 7.5; MDSC-IFN-β: 55.2 ± 5.0, p < .05) in overactivated T cells than in the control MDSCs, and a significant reduction in the proportion of viable T cells (MDSC-Veh: 65.9 ± 7.6; MDSC-IFN-β: 42.6 ± 5.1, p < .05; Fig. 10B ; Supplementary Fig. 1A-C) . Remarkably, this effect was only seen on over-activated T cells and not on control T cells, demonstrating the specificity of the effect. When we performed these same assays with a lower proportion of MDSCs (1:10), there appeared to be a similar effect on T lymphocyte cell viability and thus, stronger T cell immunosuppression, although this did not reach significance (Fig. 10C , Supplementary Fig. 1D-F) . On the other hand, the proliferation of C. Melero-Jerez, et al. Neurobiology of Disease 127 (2019) 13-31 MOG-preactivated T cells was reduced when co-cultured with both MDSC-Veh or MDSC-IFN-ß, being statistically significant in the latter (proliferation index: Stimulated splenocytes alone: 5.7 ± 0.2; MDSCsVeh: 4.7 ± 0.4, p = .120; MDSC-IFN-β: 4.1, ± 0.4, p < .05; Fig. 10E ). Together, these data indicate that MDSCs present a more powerful immunosuppressive effect after IFN-β treatment, which can also be induced ex vivo, and that affects to both policlonally activated and encephalitogenic T cells.
IFN-β maintains MDSC undifferentiated state
To explain the influence of IFN-β on MDSCs and given that the immunosuppressive activity of MDSCs is strongly determined by their state of maturity (Moliné-Velázquez et al., 2014), we carried out a timecourse analysis of the main surface marker of M-MDSCs, namely Ly-6C, and of a marker of a mature subset of cells, the macrophage marker F4/ 80. When we assessed the MFI of Ly-6C after treatment with IFN-ß, the significant loss of Ly-6C MFI after 6 h in vitro by MDSCs-Veh was not evident in the MDSC-IFN-ß. However, the Ly-6C MFI did shift in the INF-β treated MDSCs after 18 h in vitro, reaching a similar value to those in recently sorted cells (Fig. 11A) . In addition, the differentiation of the cultured MDSCs was assessed by measuring their F4/80 expression, a marker of macrophage polarization. MDSC-Veh differentiated during their time in culture to a more mature F4/80 subset, whilst the IFN-ß treated MDSCs express less F4/80 after 18 h in vitro (Fig. 11B ). All these data indicate that IFN-ß is a potent regulator of the immature MDSC immunosuppressive phenotype.
In order to determine whether INF-β produced a permanent and direct effect that preserved MDSCs in an undifferentiated state under the different co-culture conditions used in the immunosuppression experiments, we analyzed the MDSC phenotype (Ly-6C and F4/80 MFI) when cultured alone or together with activated T cells, and we compared it with the phenotype observed at the end of the IFN-β treatment (18 h). An increase in Ly-6C MFI was only stimulated in MDSCs-Veh in the presence of activated T cells (Fig. 11C) , whereas IFN-β pre-treatment predisposed MDSCs towards a significantly higher Ly-6C MFI in all culture conditions. In the case of F4/80, the high MFI observed in the MDSCs-Veh after 18 h culture did not vary significantly among the experimental groups. By contrast, the removal of IFN-β from the culture produced a significant increase in the F4/80 MFI when MDSCs were cultured alone or in the presence of unstimulated T cells, while it remained similar to that at the end of the treatment (18 h) when they were cultured together with activated T cells (Fig. 11D) . Comparing the MFI of Ly-6C between MDSCs-Veh or MDSCs-IFN-β, the latter always displayed stronger fluorescence than the former, irrespective of the presence or absence of the cytokine (Fig. 11E) . In terms of F4/80, the MFI was only weaker at the end of the treatment, while it remained similar in the rest of the conditions, i.e. when IFN-β was removed from the culture medium (Fig. 11F) . Overall, these data indicated that IFN-β prevented MDSC differentiation when added to the culture medium, exerting a persistent effect on Ly-6C expression, whereas its effect on F4/80 was fully dependent on the presence of this factor.
Discussion
In the present work, for the first time we propose that the number and suppressive capacity of MDSCs in the context of EAE is modified after IFN-ß treatment. We show that a single injection of a therapeutic dose of IFN-ß at the onset of the symptoms significantly ameliorates the clinical course of the disease. This effect parallels the increase in the presence of MDSCs in both the spleen and the infiltrated areas of the spinal cord. Moreover, MDSCs isolated from EAE mice administered IFN-β are stronger immunosuppressors, which is consistent with a higher density of apoptotic T cells in the CNS, the main target of this population (Moliné-Velázquez et al., 2011; Zhu et al., 2007) . In addition, our in vitro studies also demonstrate that IFN-β enhances the immunosuppressive effect of MDSCs on over-activated T cells possibly due to the preservation of their immature state. Although IFN-β has been shown to ameliorate RRMS by delaying the onset of new relapses, decreasing the severity of the symptoms of relapse, and/or controlling the proliferative response mediated by antigen presenting cells (APCs; Arnason, 2005; Jankovic, 2010) , our data show that the enhancement of T cell immunosuppression by MDSCs after IFN-ß administration may also contribute to this effect (Kieseier, 2011) . There are two different experimental approaches to demonstrate that the administration of IFN-ß exerts a direct effect onto MDSCs: i) to eliminate/inactivate MDSCs at the onset of the EAE course and subsequently check whether IFN-ß administration still exerts the same effect in absence of MDSCs, or ii) to transplant MDSCs from EAE-IFN-ß treated mice in recipient EAE mice just at the same moment that our therapeutic window, i.e. the onset of symptoms during the clinical course. However, due to the extremely high plasticity of the activity state in CD11b + Ly-6C high Ly-6G −/low (Ly-6C high -cells) along the EAE course, both options would bring false negative results. The elimination of Ly-6C high -cells at the onset of the disease (a cell type with an already demonstrated pro-inflammatory profile: Giles et al., 2018; King et al., 2009; Yi et al., 2012; Zhu et al., 2011) would ameliorate EAE clinical course by itself. On the other hand, the transplantation of MDSCs isolated at the peak of the disease, a moment when the molecular environment drive myeloid-infiltrating cells towards a clear anti-inflammatory activity state (Giles et al., 2018) , into EAE mice at the onset of their disease (a clinical moment with a prominent pro-inflammatory environment), may be a risk for a successful clinical course amelioration. Indeed, it has been shown that induced-MDSCs transplanted at the onset of the EAE clinical course do not result in a less severe disease course (Casacuberta-Serra et al., 2016). In our hands, although still indirect, the higher suppressive activity of MDSCs isolated from IFN-ß-treated mice, together with the abrogated proliferative promotion of Ly-6C high -cells isolated at the onset of the disease over MOG-stimulated splenocytes, suggest a direct effect of IFN-ß modifying the activity state of this plastic cell type, from purely pro-inflammatory to clearly antiinflammatory.
Indeed, different myeloid subsets infiltrating the CNS may respond to IFN-β in EAE, as is the case of blood and bone marrow derived macrophages and dendritic cells (Wlodarczyk et al., 2015) . Our data show that splenic Ly-6C high cells express IFNAR1 more strongly than the (caption on next page) C. Melero-Jerez, et al. Neurobiology of Disease 127 (2019) 13-31 general myeloid cell subset or neutrophils, and even more so than T cells, an immune cell type with particularly strong expression of this receptor (Kavrochorianou et al., 2016) . Different IFNAR-containing cell types were analyzed in gene-targeted mice to reveal the cell target of IFN-β in EAE during the effector phase of the model, including resident CNS cells, lymphocytes and myeloid cells (Prinz et al., 2008) . Myeloid cells are important for EAE disease progression, especially CD11b + Ly-6C + cells. Regarding MHC-II + -APCs, IFN-ß downregulates myelin uptake by macrophages (Prinz et al., 2008) , reducing the antigen-presenting capacity of microglial cells (Teige et al., 2006) and promoting the switch of M1 to M2 microglia (Tarassishin et al., 2011) . All these data point to IFNAR-expressing Ly-6C high myeloid cells as one of the main targets for IFN-ß during immune-mediated demyelination. Although IFN-ß has different effects on T cell biology during EAE and MS (Galligan et al., 2010; Teige et al., 2006; Trinschek et al., 2015; Rudick et al., 1993) , our current data demonstrate for the first time that the decrease in T cell activity mediated by IFN-β may also be indirectly due to the improvement of highly specialized immunosuppressive agents, e.g., MDSCs. Indeed, for several decades it has been known that IFN-ß production is a common feature of natural suppressor agents, a compilation of cell types/mechanisms that inhibit both the activity and proliferation of T cells in a non-MHC restricted manner (Cleveland et al., 1988) . In this respect, it was recently shown that IFN-ß therapy in MS patients regulates the responsiveness of activated T cells to the immunosuppression mediated by Tregs (Trinschek et al., 2015) + immature myeloid cells isolated from bone marrow-derived cells (Campillo et al., 2006) , an immunosuppressive mechanism shared with MDSCs (Melero-Jerez et al., 2016; Moliné-Velázquez et al., 2016) . We have traditionally used Arg-I to label M-MDSCs at the peak of the EAE clinical course. In this sense, all Arg-I + -cells showed immunoreactivity to the main two necessary markers to identify MDSCs by flow cytometry, i.e. CD11b and Gr-1. In addition, all Arg-I + -cells showed CD115 immunoreactivity (a good marker to discriminate MMDSCs) and none of them presented Ly-6B.2 staining (a typical marker for PMN-MDSCs or mature neutrophils). Although several reports have shown that the Arg-I + -cell population within the CNS seemed to be more heterogeneous than it was previously thought (Moliné-Velázquez et al., 2014; Giles et al., 2018) (Taleb et al., 2017) . Both these effects might be the result of: i) a direct IFN-β mediated action on MDSCs; or ii) the consequence of a more general IFN-β induced anti-inflammatory immunomodulation in both the periphery and CNS. In relation to a possible direct effect, IFN-β influences several aspects of MDSC biology. One of the most important aspects of their immunosuppressive effect is the blockage of their differentiation into mature cells, as normally occurs upon inflammatory insult, and indeed, our data suggests IFN-β impairs MDSC maturation. Although the underlying mechanism remains to be revealed, we present here the first evidence that IFN-ß maintains MDSCs in an undifferentiated state in vitro. This is probably related to how IFN-ß engages with its receptor at the cell membrane, as the effect on F4/80 expression is fully dependent on the presence of IFN-ß. In relation to MDSC maturation, the IRF8 transcription factor (Interferon Response Factor 8) is determinant for CD11b + Gr-1 + -MDSC accumulation (Scheller et al., 1999; Sonda et al., 2011; Stewart et al., 2009) , and a deficiency in IRF8 leads to abnormal hematopoiesis and it abrogates the termination of emergency granulopoiesis (Hu et al., 2016) . Such effects are consistent with our in vitro results regarding the preservation of MDSC immaturity. However, further in vivo experiments will be needed to determine if these are direct effects of IFN-β on MDSCs that are responsible for the amelioration of the clinical course of EAE.
We show an enrichment of CD11b + Arg-1 + MDSCs within the myeloid compartment in the infiltrated CNS following IFN-β treatment, within the already smaller lesions that have higher cellularity than in EAE-Veh mice. This may reflect the enhanced migration/mobilization of MDSCs towards the inflammatory sites. Although the function of Ly-6C in monocytes still remains to be determined, its blockade decreases monocyte infiltration in a mouse model of amyotrophic lateral sclerosis (Butovsky et al., 2012) . As we also demonstrated in vitro, Ly-6C expression is increased in the presence of IFN-ß and its effect persists for at least 72 h in culture. Ly-6C is a useful membrane antigen to distinguish different subpopulations of mouse blood monocytes as a function of their stage of maturation and their capacity to migrate towards inflammatory sites. Ly-6C is down-regulated in circulating blood under normal conditions but it increases after various inflammatory insults (Sunderkotter et al., 2004) . Regarding MDSC migration, the stronger expression of this molecule on monocytes is related to the so-called immature or inflammatory monocytes, i.e.: the Ly-6C high monocytes isolated at the disease onset (Saederup et al., 2010) . These cells express CCR2 (Serbina and Pamer, 2006) , a chemokine receptor absent in Ly-6C low monocytes (mature or resident monocytes), and it is closely related to their capacity to cross the BBB in EAE (Mildner et al., 2009; Saederup et al., 2010) . Therefore, the higher Ly-6C MFI in MDSCs after IFN-β treatment may indicate a greater infiltration capacity of these cells, which helps them invade the CNS of EAE mice. Interestingly, the Ly-6C gene is thought to be regulated by IFN-β since it has IFN response elements in its promoter (Dumont and Coker, 1986) . Moreover, the immunosuppressive activity of MDSCs in EAE is inversely correlated to the degree of maturation of MDSCs (Moliné-Velázquez et al., 2014) and it is directly related to the level of Ly-6C (Zhu et al., 2007) . Thus, the higher Ly-6C MFI observed in our in vitro studies may reflect a stronger T cell immunosuppressor activity. Our study confirms that modifying the density of MDSCs in the spinal cord (in this case after IFN-β treatment) parallels a greater abundance of apoptotic CD4 + T cells (Moliné-Velázquez et al., 2011) and that it is related to fewer CD3 + T cells in the spleen. Likewise, our qualitative observations on the spinal cord tissue were corroborated in vitro, given the higher immunosuppressive ability of MDSCs isolated from EAE-IFN-β mice than those from EAE-Veh mice. In support of this Fig. 9 . The immunosuppressive capacity of MDSCs is enhanced after IFN-ß treatment. A. Schematic representation of the experimental procedure quantified in B. EAE mice were administered saline or IFN-β when they had reached a clinical score between 0.5 and 1.5. Three days later, their spleens were dissected out, and MDSCs were isolated by cell sorting and exposed to control or to anti-CD3e/CD28 stimulated T cells sorted from non-immunized mice. -cells isolated at the onset of the disease promoted the proliferation of T cells, which was dampened when they were pretreated with IFN-ß. Besides, the presence of MOG in the culture of Ly-6C high -cells did not affect to this biological effect. Asterisks represent the statistical significance compared to the dashed line, and hashes compared to the respective vehicle group. n = 3/group in A-B, n = 5/ group in C-D. model, IFN-ß dampened Gr-1 expression and it enhanced the intensity of CD124 (IL4-Rα) staining, a sign of T cell apoptosis in EAE (Moliné-Velázquez et al., 2014; Zhu et al., 2007) and cancer (Gallina et al., 2006; Mandruzzato et al., 2009 as inducers of remyelination), reinforcing the pro-regenerative role of IL4-Rα in myeloid cells (Psachoulia et al., 2016) . Our in vitro data suggest that IFN-β promotes the immunosuppressive activity of MDSCs independently of the inflammatory environment. As mentioned, IFN-ß suppresses the proliferation of Th1 cells (Teige et al., 2006) , preventing the proliferation but not the viability of this cell type. However, we do not only demonstrate a decrease in the number of proliferative cells but also, an increase in the dead and apoptotic cells, as demonstrated when MDSCs were isolated from the spinal cord of EAE mice and co-cultured them with T cells (Moliné-Velázquez et al., 2011) . On the other hand, our in vitro data adds new insights into the influence of the environment in which the MDSCs develop on their immunosuppressor activity, prompting us to propose the following model: the presence of T cells stimulates the anti-inflammatory properties of MDSCs and blocks their maturation towards pro-inflammatory phenotypes. Furthermore, this physiological interaction is potentiated by the IFN-β. Further research is needed to determine the exact MDSC phenotype in humans and how these cells control the immune response in MS. To date, the participation of the different MDSC subsets in MS remains controversial. On the one hand, PMN-MDSCs are the preponderant subset in RRMS patients, with little or no participation of M-MDSCs (Ioannou et al., 2012) . On the other hand, M-MDSCs were shown to be the only subset that decreased in RRMS (Cantoni et al., 2017) . Moreover, there was no difference in the absolute number or percentage of MDSCs or of different MDSC subsets between untreated subjects or RRMS patients treated with the diseasemodifying drug, glatiramer acetate in this latter study. However, there are no reports about the number of MDSCs or the modification of the activity of these cells in MS patients treated with other compounds available in the clinic, including IFN-β. However, several studies have demonstrated the anti-inflammatory effects of IFN-β in RRMS patients, hindering T cell activation (Rudick et al., 1993) , preventing pro-inflammatory immune cells from crossing the BBB, and dampening the ability of APCs to stimulate T cells (Dhib-Jalbut and Marks, 2010) .
Based on our findings, we propose here that MDSCs might be considered a new endogenous cellular target for IFN-β. In the continued search for more effective therapeutic approaches for MS, MDSCs potentiated by IFN-β may be used as autologous agents to reduce the length of relapses and disease aggressiveness. In this respect, isolated MDSCs from RRMS patients may be potentiated ex vivo with the drug and then later autografted, thereby increasing the beneficial effects of IFN-ß and considerably limiting the side effects of this agent. Moreover, this possible ex vivo cell therapy might allow the clinical dose given to the patients to be reduced or even avoided, further diminishing the side effects of the drug (de Jong et al., 2017) . Regarding patients that do not respond to IFN-β, here we establish the basis to by-pass this failure in the response to IFN-β through the exogenous administration of this cytokine directly on MDSCs in vitro before their grafting into the bloodstream.
Conclusions
The data presented here represent the first demonstration that the quantity and the immunosuppressive activity of MDSCs appears upregulated after IFN-ß treatment. A single dose of IFN-ß after the first disease symptoms significantly ameliorated the clinical course of EAE, and it was associated with the enrichment in IFNAR-expressing MDSCs in both the peripheral immune system and the CNS. Besides, after IFN-β treatment, MDSCs showed a polarized stronger immunosuppressor phenotype, as shown by a reduction and an increase in the Gr-1/MHC-II and CD124/PD-L1 labeling, respectively. Furthermore, not only the phenotype but the immunosuppressive capacity of MDSCs over T cells was demonstrated to be potentiated after IFN-ß both in vivo and in vitro, an effect that was produced via a mechanism that may be associated with the prevention of MDSC maturation. All these data open the possibility of a future MS therapy based on autologous grafting of ex vivo potentiated MDSCs, reducing or even avoiding the side effects of current IFN-β therapy while selectively retaining the benefits of this compound.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.nbd.2019.02.014. 
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